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1. Ageing as an epigenetic disease
There is now substantial evidence that many components of 
the normal ageing syndrome are due to the accumulation of 
errors in DNA methylation (see Fraga and Esteller 2007). 
Some of the ﬁ rst evidence for the roles of epigenetic 
methylation in ageing and diseases came from studies of 
identical twins. Human monozygous (“Identical”) twins 
account for 1/250 live births. They arise from the same 
zygote and therefore have the same DNA. However, in many 
characteristics, there is a relatively high rate of discordance. 
That is, there are numerous instances where identical twins 
develop different diseases. These include some conditions 
that are seen early such as juvenile diabetes and autism, as 
well as those conditions that are seen later in life, such as 
ulcerative colitis and various cancers. There is no correlation 
between the age of onset and the concordance between twins 
(Petronis 2006). 
The cause of this high discordance is not known, but recent 
evidence suggests that differences in DNA methylation may 
be involved. One possibility is that DNA methylation 
patterns can differ between twins, even though their DNA is 
identical. If a gene becomes methylated when it should not 
be, it will be turned off, just as if the DNA had been mutated. 
One loses function either way, and methylation is a much 
easier way to lose function. Similarly, anomalies arise if a 
gene becomes unmethylated and then becomes active in the 
wrong cells.
This appears to be the case for a pair of identical twin 
girls, where one twin had a severe anomy—a duplicated 
portion of the spine in the posterior portion of her body. Her 
phenotype reminded clinicians of a similar phenotype in 
mice, wherein the Axin1 gene has been mutated. Axin is an 
inhibitor of the Wnt pathway in development, and in mice, 
mutations of the Axin1 gene cause duplications of the caudal 
axis—extra spines (and bifurcated tails). Moreover, in mice, 
methylation of the Axin1 promoter will repress the gene and 
prevent its from functioning, also giving an abnormal tail 
phenotype. Blood samples showed that although both twin 
girls had the same allele for AXIN1, there was signiﬁ cantly 
more methylation at this locus in the affected twin than in 
the unaffected twin or in the twins’ parents (Oates et al. 
2006). The regions around this gene showed no signiﬁ cant 
differences in methylation. 
Most “identical” twins, however, start off life with very 
few differences in appearance or behaviours, but accumulate 
these differences with age. Experience counts, and both 
random events and lifestyles may be reﬂ ected in phenotypes. 
Mario Fraga and colleagues in Manel Estelle’s laboratory in 
Madrid found that twin pairs were nearly indistinguishable 
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in methylation patterns when young, but older monozygous 
twins exhibited very different patterns of methylation.
This affected their gene expression patterns, such that 
older twin had different patterns of DNA expression, while 
younger twin pairs had very similar expression patterns. 
Monozygotic twin pairs start off with identical amounts 
of methylated DNA, Histone H4 acetylation, and Histone 
H3 acetylation (three epigenetic markers). However as the 
twins get older, methylation increases in both twins, but 
to different extents. Similarly, acetylation differences also 
increase. 
Not only does the amount of methylation change as twins 
age, but so does the pattern of methylation. This can be 
shown by looking at speciﬁ c genetic sequences where one 
cuts with enzymes that are sensitive to methyl groups on the 
cytosines. Thus, there are some enzymes that will cleave 
DNA at a sequence containing a C residue, but will not 
cut that sequence if the C is methylated. As twins age, the 
there is an increase in the discrepancies between the twin’s 
DNA. Therefore, methylation differences may be critical in 
causing twins to phenotypically diverge as they grow older 
and to be discordant for different diseases, as well. 
The idea that random epigenetic drift inactivates important 
genes without any particular environmental cue gives rise to 
an entirely new hypothesis of ageing. Instead of randomly 
accumulated mutations – which might be due to speciﬁ c 
mutagens – we are at the mercy of chance accumulations 
of errors made by the DNA methylating and demethylating 
enzymes. Indeed, our DNA methylating enzymes, 
unlike the DNA polymerases, are prone to errors. DNA 
methyltransferases are not the most fastidious of enzymes. 
At each round of DNA replication, they must methylate the 
appropriate Cs and leave the other Cs unmethylated, and this 
is not always done properly. 
This hypothesis of random epigenetic drift may have 
profound affects on physiology. For instance, the methylation 
of the promoter region of the estrogen receptors are known 
to increase with age (Issa et al. 1994). There is a linear 
relationship between the methylation of a promoter region in 
estrogen receptor gene with increased age. The methylation 
of the promoters of the genes for the alpha and beta estrogen 
receptors increases with age, resulting in the inactivation of 
this gene activation in the smooth muscles of the circulatory 
system. Moreover, methylation of the estrogen receptor 
genes is even more prominent in the atherosclerotic plaques 
that occlude the blood vessels. The atherosclerotic plaques 
showed more methylation of the estrogen receptor genes 
than did the tissue around it (Post et al. 1999; Kim et al. 
2007) Thus, DNA methylation associated inactivation of the 
estrogen receptor genes in vascular tissue may play a role 
in atherogenesis and ageing of the vascular system. This 
potentially reversible defect may provide a new target for 
intervention in heart disease. 
So we now have a new hypothesis for ageing. There 
appears to be random epigenetic drift that is not determined 
by the type of allele or any speciﬁ c environmental factor. 
Random epigenetic drift may cause the ageing phenotype 
as different genes randomly get repressed or ectopically 
activated. Mistakes in the DNA methylation process 
accumulate with age, and may be responsible for the 
deterioration of our physiology and anatomy. If this is 
so, some genes may be more important than others. The 
estrogen receptors, for instance, are critical in vascular, 
skeletal, and muscular health. 
2. Cancer
But there are some genes that are even more important to 
be properly regulated. These are the genes that prevent 
cancers. There are two types of genes involved in cancer 
production. The ﬁ rst are oncogenes. These are the genes that 
promote tumour formation and metastasis (spread of cancer 
cells throughout the body). They are the genes that promote 
cell division, reduce cell adhesion, and prevent cell death. 
The second set of genes are the tumour suppressor genes. 
These genes usually put breaks on cell division and increase 
the adhesion between cells. These genes also can cause 
apoptosis (cell death) of rapidly dividing cells.
These oncogenes and tumour suppressor genes have to 
be very ﬁ nely regulated. In the stem cells of the skin, gut, 
and blood, for instance, there has to be a very carefully 
controlled rate of cell division. In the epithelial cells that 
make up your kidney and lungs, cell division is much rarer. 
Thus, one might get cancers if faulty methylation either 
inappropriately methylated the tumour suppressor genes or 
inappropriately demethylated the oncogenes. 
In the breast, estrogen receptors can act as oncogenes 
for estrogen-dependent breast cancer. Moreover, in breast 
tissue, there is an age-related increase in the methylation 
of the promoter of the RASSF1A gene, whose product is a 
tumour suppressor. This methylation has been correlated 
with the risk of breast cancer (Euhus et al. 2008). In the 
colon, however, estrogen stops the proliferation of cells, 
and the estrogen receptors function as tumour-suppressor 
genes. Issa and colleagues (1994) showed that in addition 
to the age-associated methylation of the estrogen receptors, 
there was a much higher level of DNA methylation in the 
estrogen receptor genes in colon cancers. Even the smallest 
colon cancers had nearly 100% methylation of the estrogen 
receptor promotor. Moreover, microarrays (which detect 
differences in mRNA populations) identiﬁ ed numerous 
genes whose methylation patterns changed dramatically in 
colon cancer cells (Schuebel et al. 2007).
In addition to the age-related onset of tumours. DNA 
methylation can also explain the etiology (cause) of several 
lifestyle-related tumours. For instance, tobacco smoke is 
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known to cause cancer, but it is not a very powerful mutagen. 
Russo and colleagues (2005) and Liu and colleagues (2006) 
found that lung cancers caused by cigarette smoke had 
several tumour suppressor genes heavily methylated. 
These included the genes encoding cell adhesion proteins, 
apoptosis accelerators, and mitosis inhibitors. In addition, 
Liu and colleagues (2007) showed that the synuclein-
gamma gene, a gene that is not normally expressed in lung 
tissues, is activated by cigarette smoke. This gene appears to 
be demethylated, and its activation promotes the spread of 
the tumour to other parts of the body. 
The mechanism by which the synuclein-gamma gene is 
demethylated gives us an important clue as to how tumours 
can occur. The current model of tumour formation is a gene-
centered model wherein a particular cell accumulates over a 
dozen new mutations. This seems probabilistically unlikely. 
But in the cancer model presented here, DNA methylation, 
not DNA mutation, causes the deﬁ ciency of proteins. The 
cause for the demethylation of synuclei-gamma appears 
to be the downregulation of a gene that encodes the 
methyltransferase enzyme DNMT3B, which usually adds 
methyl groups to DNA. 
3. The reciprocity of epigenetic and genetic causation 
in cancer 
The epigenetic causation of cancer does not exclude a 
genetic cause. Indeed, several studies indicate that these 
mechanisms augment one another. Numerous mutations 
occur in each cancer cell, and recent evidence suggests that 
as many as fourteen signiﬁ cant tumour-promoting mutations 
are found in each cancer cell (Sjöblom et al. 2006). Feinberg 
and colleagues (2006) have proposed that the ﬁ rst stage of 
tumour development is an epigenetic alteration of the DNA 
in a progenitor cell such that it will enable mutations to 
accumulate in other portions of the genome, and Jacinco 
and Esteller (2007) have shown that the large number of 
mutations that accumulate in cancer cells has an epigenetic 
cause. DNA has several means of protecting itself from 
mutations. One is the editing subunits on DNA polymerase 
which get rid of mismatched bases and insert the correct 
ones. Another mechanism is the set of DNA repair enzymes. 
These enzymes repair DNA that has been damaged by light 
or by cellular compounds that are products of metabolism. In 
cancer cells, the genes encoding these DNA repair enzymes 
appear to be susceptible to inactivation by methylation. 
Once these DNA repair enzymes have been downregulated, 
the number of mutations increases. Therefore, ageing and 
cancer may be linked in having the common denominator of 
aberrant DNA methylation. If metabolically or structurally 
important genes (such as the estrogen receptors) become 
heavily methylated, they do not produce enough receptor 
proteins, and our body functions more poorly. If tumour 
suppressor genes or the genes encoding DNA repair enzymes 
are heavily methylated, tumours can arise. 
In this model of cancer development, genetic changes 
are not nearly as critical as the epigenetic changes. This 
provides an organizational framework for a great deal of data 
that have accumulated indicating that many cancers have 
normal genomes (reviewed in Sonnenschein and Soto 1999; 
Gilbert, 2006). Some cancer cells can actually revert back to 
being normal cells when put into appropriate environments 
or when given chemicals that cause them to differentiate 
(Stewart and Mintz 1981; Altucci and Gronemeyer 2001; 
Bissell et al. 2002). So these cancer cells have been thought 
to be epigenetically rather than genetically altered.
However, even as one ﬁ nds that epigenetic mechanisms 
may cause mutations, one also ﬁ nds that mutations can be the 
cause of epigenetic silencing. For instance, as many as 5% 
of all the genes in tumour cells might be hypermethylated 
(Schuebel et al. 2007). One of the most important oncogenes 
is the Ras small G-protein. This oncogene is known for its 
ability to initaiate signalling transduction cascades that 
phosphorylate certain transcription factors that promote 
tumourigenesis. However, Ras can also act by a second, 
epigenetic, cascade (Gazin et al. 2007). Through a pathway 
composed of at least 28 proteins (including the DNMT1 
methyltransferase), activated RAS is able to silence the 
Fas gene that enables the rapidly dividing cells to commit 
apoptosis. The active Ras protein thereby recruits DNMT1 
to the promoter of the fas gene, where it hypermethylates the 
promoter and stops its tumour-suppressor function.
Tumours can be generated by a combination of genetic 
and epigenetic means. Changes in DNA methylation can 
activate oncogenes and repress tumour-suppressor genes, 
thereby initiating tumour formation. Conversely, oncogenes 
can cause the methylation of tumour suppressor genes, 
which also aids in tumourigenesis. Moreover, the tissue 
environment of the cell may be critical in regulating 
these processes. This may be especially true in the stem 
cell niche, where ageing might allow the selection of 
oncogenic mutations (see Marusyk and DeGregori 2008). 
The complexities of tumours, including their multiple 
somatic mutations and there resistance to agents that induce 
apoptotic cell death, may best be explained by a combination 
of genetic and epigenetic factors more than just on the basis 
of mutations. Moreover, knowledge of the epigenetic causes 
of cancer can provide the basis for new methods of cancer 
therapy. 
4. Conclusion
Ageing and cancer have epigenetic components wherein 
genes can be inappropriately activated or repressed by 
demethylation and methylation. Physiologically important 
genes, when repressed, can lead to the changes seen in ageing, 
and areas of marked suppression have been associated with 
atherosclerotic plaques and other phenomena characteristic 
of the ageing syndrome. When epigenetic processes activate 
oncogenes or inactivate tumour suppressor genes, cancer 
can arise. The large number of mutations in tumour cells 
might emerge from previous epigenetic events that prevent 
DNA repair functions from taking place. These new insights 
can lead us to better preventive measures in public health 
and better treatments through drug design.
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